Our vision is to be a leader in cancer immunotherapy improving patient treatment through novel monoclonal antibodies, inducing programmed cell death in cancer cells.
Cancer treatment has generally been based on treatment with drugs and modalities that are cytotoxic to both cancer and healthy cells. Advances in immunotherapy open new possibilities for selective targeting of cancer cells.
Caedo Oncology develops new strategies for monoclonal antibody-based therapy centered around activation of distinctive pathways for cell death in cancer cells. The company was established in November 2020 based on research performed at Oslo University Hospital.
Company Details
- Employees
- 6
- Founded
- -
- Address
- Forskningsparken, Gaustadalléen 21, Oslo,0349,norway
- Industry
- Biotechnology
- Website
- http://www.caedooncology.com
- HQ
- Oslo
Caedo Oncology As Questions
Caedo Oncology As's website is http://www.caedooncology.com
Caedo Oncology As's LinkedIn profile is https://no.linkedin.com/company/caedo-oncology-as
Caedo Oncology As has
6 employees.
View email and phone details for 6
employees at Caedo Oncology As.
Caedo Oncology As's industry is
Biotechnology
Caedo Oncology As's top competitors are
Ge Healthcare,
Sharelab,
Clexbio,
Oslo Cancer Cluster,
Women In Life Science Norway (Wild Norway),
Novartis Norge,
The Life Science Cluster,
Tribune Therapeutics,
Cellmover,
Alv B As.
Caedo Oncology As's categories are Biotechnology
Caedo Oncology As's founding year is 2020
